BRPI0408274B8 - compostos de ligação de amiloide e composição farmacêutica - Google Patents

compostos de ligação de amiloide e composição farmacêutica

Info

Publication number
BRPI0408274B8
BRPI0408274B8 BRPI0408274A BRPI0408274A BRPI0408274B8 BR PI0408274 B8 BRPI0408274 B8 BR PI0408274B8 BR PI0408274 A BRPI0408274 A BR PI0408274A BR PI0408274 A BRPI0408274 A BR PI0408274A BR PI0408274 B8 BRPI0408274 B8 BR PI0408274B8
Authority
BR
Brazil
Prior art keywords
compounds
disease
pharmaceutical composition
deposit
amyloid
Prior art date
Application number
BRPI0408274A
Other languages
English (en)
Portuguese (pt)
Inventor
A Mathis Chester Jr
E Klunk William
Wang Yanming
Original Assignee
Univ Pittsburgh
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/388,173 external-priority patent/US7270800B2/en
Priority claimed from US10/645,847 external-priority patent/US20050043523A1/en
Application filed by Univ Pittsburgh, Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh
Priority claimed from PCT/US2004/007797 external-priority patent/WO2004083195A1/en
Publication of BRPI0408274A publication Critical patent/BRPI0408274A/pt
Publication of BRPI0408274B1 publication Critical patent/BRPI0408274B1/pt
Publication of BRPI0408274B8 publication Critical patent/BRPI0408274B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BRPI0408274A 2003-03-14 2004-03-15 compostos de ligação de amiloide e composição farmacêutica BRPI0408274B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/388,173 2003-03-14
US10/388,173 US7270800B2 (en) 2000-08-24 2003-03-14 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US10/645,847 2003-08-22
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses
PCT/US2004/007797 WO2004083195A1 (en) 2003-03-14 2004-03-15 Benzothiazole derivative compounds, compositions and uses

Publications (3)

Publication Number Publication Date
BRPI0408274A BRPI0408274A (pt) 2006-03-21
BRPI0408274B1 BRPI0408274B1 (pt) 2019-02-26
BRPI0408274B8 true BRPI0408274B8 (pt) 2021-05-25

Family

ID=35057877

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408274A BRPI0408274B8 (pt) 2003-03-14 2004-03-15 compostos de ligação de amiloide e composição farmacêutica

Country Status (16)

Country Link
EP (1) EP1611115B1 (enExample)
JP (1) JP4875487B2 (enExample)
CN (2) CN1784392A (enExample)
AU (2) AU2004221897B2 (enExample)
BE (1) BE2015C005I2 (enExample)
BR (1) BRPI0408274B8 (enExample)
CY (2) CY1113334T1 (enExample)
DK (1) DK1611115T3 (enExample)
ES (1) ES2393921T3 (enExample)
FR (1) FR15C0005I2 (enExample)
HU (1) HUS1500006I1 (enExample)
NO (3) NO330861B1 (enExample)
PL (1) PL1611115T3 (enExample)
PT (1) PT1611115E (enExample)
RU (1) RU2440995C2 (enExample)
SI (1) SI1611115T1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO2002016333A2 (en) 2000-08-24 2002-02-28 University Of Pittsburgh Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
WO2005118511A2 (en) * 2004-05-20 2005-12-15 The Scripps Research Institute Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
AU2008211786B2 (en) * 2007-01-30 2014-07-03 Ge Healthcare Limited Tools for aiding in the diagnosis of neurodegenerative diseases
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
US8420052B2 (en) * 2008-07-24 2013-04-16 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying AD pathology
PT2338059E (pt) * 2008-09-23 2015-08-03 Wista Lab Ltd Ligandos para moléculas de tau agregada
JP6182668B2 (ja) * 2013-09-26 2017-08-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 画像化ツールとしてのイミダゾ［１，２−ａ］ピリジン−７−アミン
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
CN103613589B (zh) * 2013-11-29 2016-03-30 江苏华益科技有限公司 一种用于神经退行性疾病领域的新型pet显像剂前体及标准品的合成方法
KR20170047341A (ko) * 2014-08-29 2017-05-04 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴 단백질을 영상화하기 위한 프로브
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
GR1009516B (el) * 2018-03-22 2019-05-02 Εκεφε Δημοκριτος Τρικαρβονυλο-συμπλοκα μεταλλων μεταπτωσεως με βενζο-ετεροκυκλικο παραγωγο του κυκλοπενταδιενυλικου ανιοντος με υψηλη διαπερατοτητα του αιματοεγκεφαλικου φραγμου για εφαρμογες στη διαγνωση και θεραπεια νοσων του κνς
CN119462558B (zh) * 2024-10-18 2025-09-19 河南中医药大学 一种布美他尼衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID22275A (id) * 1996-11-22 1999-09-23 Elan Pharm Inc Komposisi farmasi yang terdiri dari derivat asam amino n-(aril atau heteroaril) dan metode untuk menghambat pelepasan b-amiloid peptida dan atau sintesisnya dengan menggunakan senyawa tersebut
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
WO2002016333A2 (en) * 2000-08-24 2002-02-28 University Of Pittsburgh Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
EP1345914A1 (en) * 2000-12-22 2003-09-24 AstraZeneca AB Therapeutic compounds
KR20040058111A (ko) * 2001-04-23 2004-07-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아밀로이드 플라크 응집 억제제 및 진단 영상화제
GB0229686D0 (en) * 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles

Also Published As

Publication number Publication date
AU2004221897B2 (en) 2010-11-18
ES2393921T3 (es) 2013-01-02
AU2011200667A1 (en) 2011-03-10
PL1611115T3 (pl) 2013-01-31
BRPI0408274B1 (pt) 2019-02-26
AU2004221897A2 (en) 2004-09-30
EP1611115A1 (en) 2006-01-04
NO20054674D0 (no) 2005-10-11
JP4875487B2 (ja) 2012-02-15
RU2440995C2 (ru) 2012-01-27
NO20110980L (no) 2005-12-13
SI1611115T1 (sl) 2012-12-31
FR15C0005I2 (fr) 2015-07-24
NO2015005I1 (no) 2015-03-02
HK1086270A1 (en) 2006-09-15
NO2015005I2 (no) 2015-02-18
CN102532055A (zh) 2012-07-04
NO330861B1 (no) 2011-08-01
HUS1500006I1 (hu) 2015-02-18
CN102532055B (zh) 2016-05-11
AU2004221897A1 (en) 2004-09-30
BRPI0408274A (pt) 2006-03-21
AU2004221897A9 (en) 2009-08-20
AU2011200667B2 (en) 2011-12-22
PT1611115E (pt) 2012-12-07
CY2015007I1 (el) 2015-12-09
NO20054674L (no) 2005-12-13
JP2006522104A (ja) 2006-09-28
CY1113334T1 (el) 2015-12-09
DK1611115T3 (da) 2012-11-26
RU2005131872A (ru) 2006-02-27
CN1784392A (zh) 2006-06-07
BE2015C005I2 (enExample) 2023-03-07
EP1611115B1 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
BR0113470A (pt) Composto de ligação amilóide, composição farmacêutica e métodos de sìntese de composto, de detecção in vivo de depósitos amilóides num indivìduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou post-mortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal
BRPI0408274B8 (pt) compostos de ligação de amiloide e composição farmacêutica
Christie et al. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy
Xu et al. Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats
ES2520047T3 (es) Métodos de prevención, tratamiento y diagnóstico de trastornos de la agregación de proteínas
Han et al. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-β peptide, partial restoration via γ-secretase inhibition
Castellani et al. Alzheimer disease
Ballesteros-Alvarez et al. Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer’s disease
BR112012026249A2 (pt) composto, formulação radiofarmacêutica, composição farmacêutica, uso do composto, mistura, métodos de coletar dados para o diagnóstico de uma doença ou condição associadascom amiloide, de determinar a extensão de carga amiloidogênica de placas em um tecido e/ou um fluido corporal, de coletar dados para determinar uma predisposição a uma doença ou condição associadas com amiloide em um paciente, de coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina, de coletar dados para predizer capacidade de reação de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste.
TW200736252A (en) Novel heteroaryl substituted benzothiazoles
Li et al. Icariin, a major constituent of flavonoids from Epimedium brevicornum, protects against cognitive deficits induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats
WO2010011964A3 (en) Imaging agents useful for identifying ad pathology
Jiang et al. RBD and neurodegenerative diseases
WO2009003147A1 (en) Methods and compositions for the treatment of neurological disorders
BRPI0413556A (pt) sondas para doenças onde amilóide se acumula, agentes para tingimento de amilóide, drogas para tratamento e profilaxia de doenças com amilóide acumulada e sondas para diagnóstico de emaranhados neurofibrilares e agentes para tingimento de emaranhados neurofibrilares
BRPI0918194A2 (pt) ''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
Beyreuther et al. Antinociceptive efficacy of lacosamide in rat models for tumor-and chemotherapy-induced cancer pain
Veurink et al. Review genetics, lifestyle and the roles of amyloid β and oxidative stress in Alzheimer’s disease
ATE470151T1 (de) Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
Small Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer’s disease: do we need new inhibitors?
Murphy et al. Impaired skeletal muscle health in Parkinsonian syndromes: clinical implications, mechanisms and potential treatments
WO2004064869A3 (en) Amyloid-binding, metal-chelating agents
Hector et al. Hippocampal injections of soluble amyloid-beta oligomers alter electroencephalographic activity during wake and slow-wave sleep in rats
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
Takeda et al. Elevation of plasma β-amyloid level by glucose loading in Alzheimer mouse models

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/02/2019, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.